Heterozygous Familial Hypercholesterolemia Drugs Market
Global Heterozygous Familial Hypercholesterolemia Drugs Market Size, Share & Trends Analysis Report By Type (Gemcabene Calcium, MGL-3196, ST- 103 and Others), By Application (Hospital, Medical Center, Clinics and Others) Forecast 2022-2028 Update Available - Forecast 2024-2030
The global heterozygous familial hypercholesterolemia drug market is anticipated to grow at a considerable CAGR during the forecast period. Heterozygous familial hypercholesterolemia, an inherited genetic disorder that can cause a hike in the cholesterol level of the body which further lead to cardiac arrest or stroke if not kept in control. It is mainly caused by genes that are passed upon by ancestors in humans. High cholesterol levels end up damaging artery, which is responsible to carry blood and oxygen from the heart to the rest of the body. It is because of high cholesterol levels that heart attacks are quite common these days in young age groups. For instance, as per the paper published in the New England journal of medicine, in April 2020, Young adults who received inclisiran were seen to have a lower level of cholesterol level, which were given this dose consistently. The increasing high cholesterol levels among population can lead to the more demand for heterozygous familial hypercholesterolemia drugs Due to high cholesterol level the risk for heart disease increasing leading to death, and for stroke. This is further projected to create demand for heterozygous familial hypercholesterolemia drug during forecasted period.
Impact of COVID-19 Pandemic on Global Heterozygous familial hypercholesterolemia drug market
Covid-19 Pandemic has affected every sector of the world in some way. The supply of drugs in the market was affected due to nationwide lockdown in almost all countries in the world. This market got affected for a short period. Consumption of these drugs also went down as hospitals facility were closed at this time. Such drugs are prescribed by health experts on careful observation and people were not able to visit medical facilities during pandemics.
Segmental Outlook
The global heterozygous familial hypercholesterolemia drug market is segmented based on type and application. Based on type, the market is segmented into Gemcabene calcium, MGL-3196, ST- 103, and others. Based on application the market is sub-segmented into hospitals, medical center, clinics, and others.
Global Heterozygous familial hypercholesterolemia drugs market Share by type, 2021 (%)
Gemcabene Calcium is anticipated to Hold a Prominent Share in the Global Heterozygous familial Hypercholesterolemia Drug Market
Gemcabene calcium is anticipated to hold a prominent market share in the global heterozygous familial hypercholesterolemia drug market during the forecast period. Gemcabene calcium has a structure of a small molecule and is used to lower inflammatory conditions. This was discovered in a study of cytokine induction which was showing inhibition. The conclusion was made that this drug acts as an anti-inflammatory component. Efficacy of this drug was observed in a rat model of carrageenan-induced thermal hyperalgesia. This was also done in collagen-induced joint swelling and arthritis and the results were similar. In the model which was made upon a mouse-induced monoclonal antibody, a dependent dose was observed in joint swelling. For instance, In Oct 2020, in a study which was published in the New England journal of medicine, in which a total of 157 patients were given evolocumab. Significant changes were observed in patients as their cholesterol level went down by 44 percent.
Regional Outlooks
The global heterozygous familial hypercholesterolemia drug market is further segmented based on geography including North America (the US, and Canada), Europe (Italy, Spain, Germany, France, and Others), Asia-Pacific (India, China, Japan, South Korea, and Others), and the Rest of the World (the Middle East &Africa, and Latin America).
Global Heterozygous Familial Hypercholesterolemia Drug Market Growth, by Region 2022-2028
North America is Estimated to Hold the Major Share in the Global Heterozygous Familial Hypercholesterolemia Drug Market
Geographically, it is anticipated that the major share of the market will be taken by North America and this region will lead during the forecast period. A major reason for this is the intake of food that has high cholesterol levels. Dairy products such as whole milk, butter, full-fat yogurt, and cheese are high in saturated fat. Apart from this, fried food and processed meat are responsible for high cholesterol. There is high consumption of these foods in the North American region, which in turn leads to high cholesterol levels. High cholesterol among children and young population due to consumption of fast foods is the major cause of heterozygous familial hypercholesterolemia. For instance, 7% of U.S. children and adolescents ages 6 to 19 have high total cholesterol. High cholesterol is linked with a higher risk of cardiovascular disease which include coronary heart disease, stroke, and peripheral vascular disease.
Market Players Outlook
The major companies serving the global heterozygous familial hypercholesterolemia drug market include Daewoong Corp.Ltd., Esperion Therapeutics, Inc., Gemphire Therapeutics, Inc., Madrigal Pharmaceuticals Inc., Abbvie Inc., and others. The market players are adopting different market strategies such as mergers and acquisitions, new product launches, business expansion, partnership collaboration, and others. For instance, in Feb 2021, FDA approves Regeneron’s drug Evkeeza. This drug would be used for the treatment of rare forms of disease which cause high cholesterol levels.
The Report Covers
- Market value data analysis of 2021 and forecast to 2028.
- Annualized market revenues ($ million) for each market segment.
- Country-wise analysis of major geographical regions.
- Key companies operating in the global Heterozygous familial hypercholesterolemia drug market. Based on the availability of data, information related to new product launches, and relevant news is also available in the report.
- Analysis of business strategies by identifying the key market segments positioned for strong growth in the future.
- Analysis of market entry and market expansion strategies.
- Competitive strategies by identifying ‘who-stands-where’ in the market.
1. Report Summary
• Current Industry Analysis and Growth Potential Outlook
• Impact of COVID-19 on The Global Heterozygous familial hypercholesterolemia drugs Market
• Recovery Scenario of Global Heterozygous familial hypercholesterolemia drugs Market
1.1. Research Methods and Tools
1.2. Market Breakdown
1.2.1. By Segments
1.2.2. BY Region
2. Market Overview and Insights
2.1. Scope of the Report
2.2. Analyst Insight & Current Market Trends
2.2.1. Key Findings
2.2.2. Recommendations
2.2.3. Conclusion
3. Competitive Landscape
3.1. Daewoong Corp.Ltd.
3.1.1. Overview
3.1.2. Financial Analysis
3.1.3. SWOT Analysis
3.1.4. Recent Developments
3.2. Esperion Therapeutics Inc.
3.2.1. Overview
3.2.2. Financial Analysis
3.2.3. SWOT Analysis
3.2.4. Recent Developments
3.3. Gemphire Therapeutics Inc.
3.3.1. Overview
3.3.2. Financial Analysis
3.3.3. SWOT Analysis
3.3.4. Recent Developments
3.4. Madrigal Pharmaceuticals Inc.
3.4.1. Overview
3.4.2. Financial Analysis
3.4.3. SWOT Analysis
3.4.4. Recent Developments
3.5. Abbvie Inc.
3.5.1. Overview
3.5.2. Financial Analysis
3.5.3. SWOT Analysis
3.5.4. Recent Developments
3.6. Key Strategy Analysis
3.7. Impact of Covid-19 on Key Players
4. Market Segmentation
4.1. Global Heterozygous Familial Hypercholesterolemia Drugs Market By Type
4.1.1. Gemcabene calcium
4.1.2. MGL-3196
4.1.3. ST-103
4.1.4. Others
4.2. Global Heterozygous Familial Hypercholesterolemia Drugs Market By End-User
4.2.1. Hospital
4.2.2. Medical center
4.2.3. Clinics
4.2.4. Others
5. Regional Analysis
5.1. North America
5.1.1. United States
5.1.2. Canada
5.2. Europe
5.2.1. UK
5.2.2. Germany
5.2.3. Italy
5.2.4. Spain
5.2.5. France
5.2.6. Rest of Europe
5.3. Asia-Pacific
5.3.1. China
5.3.2. India
5.3.3. Japan
5.3.4. South Korea
5.3.5. Rest of Asia-Pacific
5.4. Rest of the World
6. Company Profiles
6.1. Aegerion Pharmaceuticals Inc.
6.2. Amgen Inc.
6.3. AstraZeneca Plc
6.4. Daiichi Sankyo Company Ltd.
6.5. Esperion Therapeutics, Inc.
6.6. Merck & Co., Inc
6.7. Novartis AG
6.8. Pfizer Inc.
6.9. Sanofi S.A.
1. GLOBAL HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA DRUGS MARKET RESEARCH AND ANALYSIS BY TYPE, 2021-2028 ($ MILLION)
2. GLOBAL GEMCABENE CALCIUM HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA DRUGS MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
3. GLOBAL MGL-3196 HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA DRUGS MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
4. GLOBAL ST-103 HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA DRUGS MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
5. GLOBAL OTHER HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA DRUGS MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
6. GLOBAL HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA DRUGS MARKET RESEARCH AND ANALYSIS BY END-USER, 2021-2028 ($ MILLION)
7. GLOBAL HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA DRUG IN HOSPITAL MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
8. GLOBAL HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA DRUG IN MEDICAL CENTER MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
9. GLOBAL HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA DRUG IN CLINICS MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
10. GLOBAL HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA DRUG MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
11. GLOBAL HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA DRUG IN OTHER END-USER MARKET RESEARCH AND ANALYSIS BY GEOGRAPHY, 2021-2028 ($ MILLION)
12. NORTH AMERICAN HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA DRUG MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2021-2028 ($ MILLION)
13. NORTH AMERICAN HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA DRUG MARKET RESEARCH AND ANALYSIS BY TYPE, 2021-2028 ($ MILLION)
14. NORTH AMERICAN HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA DRUG MARKET RESEARCH AND ANALYSIS BY END-USER, 2021-2028 ($ MILLION)
15. EUROPEAN HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA DRUG MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2021-2028 ($ MILLION)
16. EUROPEAN HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA DRUG MARKET RESEARCH AND ANALYSIS BY TYPE, 2021-2028 ($ MILLION)
17. EUROPEAN HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA DRUG MARKET RESEARCH AND ANALYSIS BY END-USER, 2021-2028 ($ MILLION)
18. ASIA-PACIFIC HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA DRUG MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2021-2028 ($ MILLION)
19. ASIA-PACIFIC HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA DRUG MARKET RESEARCH AND ANALYSIS TYPE, 2021-2028 ($ MILLION)
20. ASIA-PACIFIC HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA DRUG MARKET RESEARCH AND ANALYSIS BY END-USER, 2021-2028 ($ MILLION)
21. REST OF THE WORLD HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA DRUG MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2021-2028 ($ MILLION)
22. REST OF THE WORLD HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA DRUG MARKET RESEARCH AND ANALYSIS BY TYPE, 2021-2028 ($ MILLION)
23. REST OF THE WORLD HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA DRUG MARKET RESEARCH AND ANALYSIS BY END-USER, 2021-2028 ($ MILLION)
1. IMPACT OF COVID-19 ON GLOBAL HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA DRUG MARKET, 2021-2028 ($ MILLION)
2. IMPACT OF COVID-19 ON GLOBAL HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA DRUG MARKET BY SEGMENT, 2021-2028 ($ MILLION)
3. RECOVERY OF GLOBAL HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA DRUG MARKET, 2021-2027 (%)
4. GLOBAL HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA DRUG MARKET SHARE BY TYPE, 2021 VS 2028 (%)
5. GLOBAL GEMCABENE CALCIUM HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA DRUG MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
6. GLOBAL MGL-3196 HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA DRUG MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
7. GLOBAL ST-103HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA DRUG MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
8. GLOBAL OTHER HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA DRUGs MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
9. GLOBAL HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA DRUG MARKET SHARE BY END-USER, 2021 VS 2028 (%)
10. GLOBAL HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA DRUG IN HOSPITAL MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
11. GLOBAL HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA DRUG IN MEDICAL CENTER MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
12. GLOBAL HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA DRUG IN CLINIC MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
13. GLOBAL HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA DRUG IN OTHER END-USERS MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
14. GLOBAL HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA DRUG MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
15. US HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA DRUG MARKET SIZE, 2021-2028 ($ MILLION)
16. CANADA HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA DRUG MARKET SIZE, 2021-2028 ($ MILLION)
17. UK HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA DRUG MARKET SIZE, 2021-2028 ($ MILLION)
18. FRANCE HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA DRUG MARKET SIZE, 2021-2028 ($ MILLION)
19. GERMANY HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA DRUG MARKET SIZE, 2021-2028 ($ MILLION)
20. ITALY HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA DRUG MARKET SIZE, 2021-2028 ($ MILLION)
21. SPAIN HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA DRUG MARKET SIZE, 2021-2028 ($ MILLION)
22. REST OF EUROPE HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA DRUG MARKET SIZE, 2021-2028 ($ MILLION)
23. INDIA HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA DRUG MARKET SIZE, 2021-2028 ($ MILLION)
24. CHINA HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA DRUG MARKET SIZE, 2021-2028 ($ MILLION)
25. JAPAN HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA DRUG MARKET SIZE, 2021-2028 ($ MILLION)
26. SOUTH KOREA HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA DRUG MARKET SIZE, 2021-2028 ($ MILLION)
27. REST OF ASIA-PACIFIC HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA DRUG MARKET SIZE, 2021-2028 ($ MILLION)
28. REST OF THE WORLD HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA DRUG MARKET SIZE, 2021-2028 ($ MILLION)
